Patents by Inventor Moosa Mohammadi
Moosa Mohammadi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210054355Abstract: Disclosed herein are modified soluble ?-Klotho proteins and isolated fragments of wildtype soluble ?-Klotho protein. Also disclosed are pharmaceutical compositions including the modified soluble ?-Klotho proteins and/or isolated fragments of soluble ?-Klotho protein and methods of their use in treating a subject.Type: ApplicationFiled: January 11, 2019Publication date: February 25, 2021Inventor: Moosa MOHAMMADI
-
Publication number: 20200384079Abstract: Pharmaceutical compositions of native and engineered mutant Fibroblast Growth Factors (FGFs) and methods for treating patients undergoing ischemic cardiac reperfusion therapy to reduce or eliminate ischemic reperfusion injury, methods for treating patients suffering from or suspected of suffering from a myocardial infarction and about to undergo or undergoing cardiac reperfusion therapy to reduce extent of the myocardial infarction, and methods for treating patients who suffered a cardiac ischemic event to restore cardiac function to a pre-ischemic event level of cardiac function by administering a native or engineered mutant FGF, and, optionally, heparin.Type: ApplicationFiled: April 26, 2018Publication date: December 10, 2020Inventors: Jo El J. Schultz, Moosa Mohammadi
-
Patent number: 10703788Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF21 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: GrantFiled: February 13, 2018Date of Patent: July 7, 2020Assignee: New York UniversityInventors: Moosa Mohammadi, Regina Goetz
-
Patent number: 10633424Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: GrantFiled: February 14, 2018Date of Patent: April 28, 2020Assignee: New York UniversityInventors: Moosa Mohammadi, Regina Goetz
-
Patent number: 10464979Abstract: Disclosed herein are FGF23 c-tail fusion proteins, pharmaceutical compositions comprising the FGF23 c-tail fusion proteins, and methods of treatment using the FGF23 c-tail fusion proteins. This application discloses fusion proteins comprising a FGF-23 c-tail protein fused to a heterologous amino acid sequence, wherein said fusion protein modulates serum phosphate levels but does not substantially modulate serum 1, 25 VitD levels. In some embodiments, the FGF-23 c-tail protein is fused to the heterologous amino acid sequence via a linker. This invention also encompasses vectors comprising the nucleic acids disclosed herein, and a host cell comprising the vector or polynucleotides encoding the proteins of the invention.Type: GrantFiled: March 30, 2015Date of Patent: November 5, 2019Assignees: New York University, Pfizer Inc.Inventors: Moosa Mohammadi, Regina Goetz, Jeanne Sue Magram, Kristen Leigh Johnson
-
Patent number: 10364278Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF23 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from a disorder, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: GrantFiled: May 18, 2017Date of Patent: July 30, 2019Assignee: New York UniversityInventors: Moosa Mohammadi, Regina Goetz
-
Patent number: 10174090Abstract: The present invention relates to chimeric proteins that include an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion of fibroblast growth factor 21 (“FGF21”) and the C-terminus includes a C-terminal portion of fibroblast growth factor 19 (“FGF19”). The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, as well as methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, methods of treating a subject in need of increased FGF21-?Klotho-FGF receptor complex formation, methods of causing increased FGF21 receptor agonist-?Klotho-FGF receptor complex formation, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: GrantFiled: October 3, 2016Date of Patent: January 8, 2019Assignee: New York UniversityInventors: Moosa Mohammadi, Regina Goetz
-
Publication number: 20180186850Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: ApplicationFiled: February 14, 2018Publication date: July 5, 2018Inventors: Moosa MOHAMMADI, Regina GOETZ
-
Publication number: 20180186849Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF21 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: ApplicationFiled: February 13, 2018Publication date: July 5, 2018Inventors: Moosa MOHAMMADI, Regina GOETZ
-
Patent number: 9926356Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: GrantFiled: October 10, 2016Date of Patent: March 27, 2018Assignee: New York UniversityInventors: Moosa Mohammadi, Regina Goetz
-
Patent number: 9926355Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF21 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: GrantFiled: October 10, 2016Date of Patent: March 27, 2018Assignee: New York UniversityInventors: Moosa Mohammadi, Regina Goetz
-
Patent number: 9907830Abstract: The present invention is directed to a method of treating chronic kidney disease. This method involves selecting a subject with chronic kidney disease and administering to the selected subject an inhibitor of FGF23-Klotho-FGF receptor complex formation under conditions effective to treat the chronic kidney disease. The present invention is also directed to a method of treating or preventing chronic kidney disease symptoms and/or complications, which involves selecting a subject with a chronic kidney disease symptom and/or complication and and administering to the selected subject an inhibitor of FGF23-Klotho-FGF receptor complex formation under conditions effective to treat the chronic kidney disease.Type: GrantFiled: February 8, 2013Date of Patent: March 6, 2018Assignee: New York UniversityInventors: Moosa Mohammadi, Regina Goetz
-
Publication number: 20170355738Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF23 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from a disorder, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: ApplicationFiled: May 18, 2017Publication date: December 14, 2017Inventors: Moosa MOHAMMADI, Regina GOETZ
-
Publication number: 20170226172Abstract: Disclosed herein are FGF23 c-tail fusion proteins, pharmaceutical compositions comprising the FGF23 c-tail fusion proteins, and methods of treatment using the FGF23 c-tail fusion proteins. This application discloses fusion proteins comprising a FGF-23 c-tail protein fused to a heterologous amino acid sequence, wherein said fusion protein modulates serum phosphate levels but does not substantially modulate serum 1, 25 VitD levels. In some embodiments, the FGF-23 c-tail protein is fused to the heterologous amino acid sequence via a linker. This invention also encompasses vectors comprising the nucleic acids disclosed herein, and a host cell comprising the vector or polynucleotides encoding the proteins of the invention.Type: ApplicationFiled: March 30, 2015Publication date: August 10, 2017Inventors: Moosa MOHAMMADI, Regina Goetz, Jeanne Sue MAGRAM, Kristen Leigh JOHNSON
-
Patent number: 9657075Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF23 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from a disorder, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: GrantFiled: March 15, 2013Date of Patent: May 23, 2017Assignee: New York UniversityInventors: Moosa Mohammadi, Regina Goetz
-
Publication number: 20170101449Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF 19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: ApplicationFiled: October 10, 2016Publication date: April 13, 2017Inventors: Moosa MOHAMMADI, Regina GOETZ
-
Publication number: 20170096462Abstract: The present invention relates to chimeric proteins that include an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion of fibroblast growth factor 21 (“FGF21”) and the C-terminus includes a C-terminal portion of fibroblast growth factor 19 (“FGF19”). The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, as well as methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, methods of treating a subject in need of increased FGF21-?Klotho-FGF receptor complex formation, methods of causing increased FGF21 receptor agonist-?Klotho-FGF receptor complex formation, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: ApplicationFiled: October 3, 2016Publication date: April 6, 2017Inventors: Moosa Mohammadi, Regina GOETZ
-
Publication number: 20170029480Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF21 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: ApplicationFiled: October 10, 2016Publication date: February 2, 2017Inventors: Moosa MOHAMMADI, Regina GOETZ
-
Patent number: 9550820Abstract: The present invention relates to an isolated chimeric protein. The isolated chimeric protein includes an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion from a fibroblast growth factor (“FGF”) 23 molecule and the C-terminus includes a C-terminal portion from an FGF19 molecule. The present invention also relates to a pharmaceutical composition including an isolated chimeric protein and a pharmaceutically acceptable carrier. The isolated chimeric protein includes an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion from a fibroblast growth factor (“FGF”) 23 molecule and the C-terminus includes a C-terminal portion from an FGF19 molecule, and a pharmaceutically-acceptable carrier. Yet another aspect of the present invention relates to a method for treating a subject suffering from a disorder.Type: GrantFiled: February 20, 2014Date of Patent: January 24, 2017Assignee: New York UniversityInventors: Moosa Mohammadi, Regina Goetz
-
Patent number: 9475856Abstract: The present invention relates to chimeric proteins that include an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion of fibroblast growth factor 21 (“FGF21”) and the C-terminus includes a C-terminal portion of fibroblast growth factor 19 (“FGF19”). The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, as well as methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, methods of treating a subject in need of increased FGF21-?Klotho-FGF receptor complex formation, methods of causing increased FGF21 receptor agonist-?Klotho-FGF receptor complex formation, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.Type: GrantFiled: March 4, 2013Date of Patent: October 25, 2016Assignee: New York UniversityInventors: Moosa Mohammadi, Regina Goetz